Promising new treatments for rheumatoid arthritis: The kinase inhibitors

Bulletin of the NYU Hospital for Joint Diseases

Volumn 69, Issue 3, 2011, Pages 233-237

  Yazici, Yusuf ^a   Regens, Alexandra L ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CHLOROQUINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOSTAMATINIB; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; TASOCITINIB;

ACUTE HEART FAILURE; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; DIARRHEA; DRUG WITHDRAWAL; HUMAN; NEUTROPENIA; OPPORTUNISTIC INFECTION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; TRAUMATIC BRAIN INJURY; UPPER RESPIRATORY TRACT INFECTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JANUS KINASES; OXAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRIMIDINES; PYRROLES; TREATMENT OUTCOME;

EID: 80054091495     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Yazici Y. Treatment of rheumatoid arthritis: we are getting there. Lancet. 2009;374: 210-1.
2. Bonilla-Hernan MG, Miranda-Carus ME, Martin-Mola E. New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors. Rheumatology. 2011;50:1542-50.
3. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60:1895-905.
4. Kremer JM, Cohen S, Wilkinson B, et al. Safety and efficacy after 24 week (WK) dosing of the oral JAK inhibitor CP-690,550 (CP) in combination with methotrexate (MTX) in patients (PTS) with active rheumatoid arthritis (RA). Arthritis Rheum. 2009;60(Suppl 719):1925.
5. Kanik K, Fleischmann R, Cutolo M, et al. Phase 2B dose ranging monotherapy study of the oral JAK inhibitor CP-690,550 (CP) or adalimumab (ADA) vs placebo (PBO) in patients (pts) with active rheumatoid arthritis (RA) withan inadequate response to DMARDs. Ann Rheum Dis. 2009;68:123.
6. Tanaka Y, Suzuki M, Nakamura H, et al. Phase II Study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken). 2011;63(8):1150-8.
7. Kremer J, Li ZG, Hall S, et al. Tofacitinib (CP-690,550), an oral JAK inhibitor, in combination with traditional DMARDs: phase 3 study in patients with active rheumatoid arthritis with inadequate response to DMARDs. Ann Rheum Dis. 2011;70(Suppl3):170.
8. Kim JW, Choi IA, Lee EY, et al. Tasocitinib monotherapy can prevent radiographic progression in rheumatoid arthritis. Ann Rheum Dis. 2011;70(Suppl3):599.
9. Braselmann S, Taylor V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006;319:998-1008.
10. Weinblatt ME, Kavanaugh A, Genovese MC, et al., An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis., N Engl J Med., 2010;363(14);1303-12.
11. Yazici Y, Yazici H, Pincus T. Differences in levels of disease activity in rheumatoid arthritis patients from different countries. Lett Ed Rheumatol. 1(1):e110001. doi:10.2399/ ler.11.0001.
12. Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase ii study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 2011;63:337-45.